AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia

Recruitingn/aAges 2 Years - 65 YearsAllSYSNAV
💬

In plain words

What the trial is, and whether it could suit you

The study aims to identify which Syde®-derived digital outcomes are reliable in FGFR3-related Skeletal Dysplasia. This requires to set-up a natural history study to measure limb movements in patients with ACH or HCH.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1.a. Aged 2 years old or older at the time of consent (France and Belgium) 1. b. Aged between 2 years old and \< 17 years old at the time of consent (United Kingdom) 2. Written informed consent obtained: 1. From the parent(s) or legal guardian(s) for participants under 18 years old. 2. From participants 18 years old and older. 3. Affiliated to, or beneficiary of a social security category (not applicable for the United Kingdom) 4. Able to walk unassisted for at least 10 meters. 5. Genetically confirmed diagnosis with one pathogenic variant (ACMG class IV \& V) of achondroplasia or hypochondroplasia. 6. Participant (and caregivers for participants under 18 years old) willing and able to comply with all study procedures including: questionnaires, Syde® related procedures Exclusion Criteria: 1. Subjects who have short stature condition other than ACH/HCH. 2. Presence of cognitive disorders that limit their understanding of the data collection process (training of device use and 4-week recording periods every 6 months, device return at the end of the study), the implication of the study and consent. 3. Presence or history of any concurrent disease or condition that could interfere with study participation, impact pediatric growth, affect motor or balance or gait function (such as neurological, endocrine, infectious, allergic, osteoarthritis, or inflammatory), assessed by the investigator. 4. Females who are pregnant, or planning to become pregnant during the study duration. 5. Body Mass Index = 35 kg/m2. 6. Recent upper and/or lower limbs injury (trauma/fracture or surgery) in the 6 months preceding inclusion. 7. Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study. 8. Presence of guided growth hardware (such as 8-plates) or planned orthopedic surgeries during the study. 9. Vulnerable patient (guardianship, curatorship or safeguarding of justice), unable to provide informed consent or who is unable to express their consent.
💊

What it tests

  • Not listed
📍

Where

4 sites
CHU de Liège
Liège, Belgium
Hôpital de la Citadelle
Liège, Belgium
Hopital Necker
Paris, France
Myriad Trials
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy